James R Lawter

This inventor holds 16 USPTO granted patents, plus 3 CIPO patents and 2 EPO patents. Top assignees: American Cyanamid Company, Qlt Inc., Immunex Corporation. Active years: 1989-2006.

IDiyas Innovation Intelligence. (2026). Inventor Profile: James R Lawter. Retrieved from https://idiyas.com/inventor/james-r-lawter

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 16

% Patents Active = 93.8

CIPO Patents = 3 (Patent Applications = 1)

EPO Patents = 2 (Patent Applications = 1)

Average Co-Inventor Count = 2.5

ph-index = 13

Forward Citations = 1,061(Granted Patents)

Location History:

Orange, NY (US) (1991 - 1992)
Goshen, NY (US) (1989 - 2006)

Company Filing History:

13 out of 3,580

American Cyanamid Company

Quadra Logic Technologies, Inc.

patents

where one patent can have more than one assignee

Years Active: 1989-2006

Loading Chart...

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 7135193 - Liposome compositions of porphyrin photosensitizers (2006-11-14),

2. 6890555 - Liposome compositions of porphyrin photosensitizers (2005-05-10),

3. 5942253 - Prolonged release of GM-CSF (1999-08-24),

4. 5622498 - Method for the treatment of periodontal disease by sustained delivery of (1997-04-22),

5. 5500228 - Phase separation-microencapsulated pharmaceuticals compositions useful (1996-03-19),

6. 5366733 - Method for the treatment of periodontal disease by sustained delivery of (1994-11-22),

7. 5280018 - Vehicle for optical application of pharmaceuticals (1994-01-18),

8. 5236355 - Apparatus for the treatment of periodontal disease (1993-08-17),

9. 5143661 - Silicone-hardened pharmaceutical microcapsules (1992-09-01),

10. 5114946 - Transdermal delivery of pharmaceuticals (1992-05-19),

11. 5059619 - Stable freeze-dried polyhematoporphyrin ether/ester (1991-10-22),

12. 5055456 - Anti-alopecia composition (1991-10-08),

13. 5001139 - Enchancers for the transdermal flux of nivadipine (1991-03-19),

14. 5000886 - Silicone-hardened pharmaceutical microcapsules and process of making the (1991-03-19),

15. 4992445 - Transdermal delivery of pharmaceuticals (1991-02-12),

Title: The Innovative Journey of James R. Lawter

Introduction

James R. Lawter, an esteemed inventor based in Goshen, NY, has made significant contributions to the field of pharmaceutical formulations with his pioneering work. With a remarkable portfolio of 16 patents, he has carved a niche for himself in the realm of liposomal compositions and their applications in photodynamic therapy.

Latest Patents

One of Lawter's latest patents revolves around liposome compositions of porphyrin photosensitizers. These liposomal pharmaceutical formulations incorporate porphyrin photosensitizers which are particularly valuable for the photodynamic therapy or diagnosis of malignant cells. The formulations feature hydro-mono benzoporphyrins, known for their light absorption maxima in the range of 670–780 nanometers, a disaccharide or polysaccharide, along with one or more phospholipids. This innovative approach not only enhances therapeutic efficacy but also opens avenues for targeted cancer treatments.

Career Highlights

Throughout his career, James R. Lawter has held notable positions at reputable organizations, including the American Cyanamid Company and QLT Inc. His work has helped advance the understanding and application of liposome technology in modern medicine, showcasing his commitment to improving healthcare solutions through innovation.

Collaborations

Lawter has collaborated with distinguished professionals in the field, such as Michael G. Lanzilotti and John M. Pawelchak. These collaborations have enriched his research and contributed to the groundbreaking work in liposomal formulations, leading to advancements in cancer diagnosis and treatment.

Conclusion

James R. Lawter's contributions to the field of pharmaceuticals through his inventive spirit and dedication are commendable. His innovative liposomal compositions continue to pave the way for new therapeutic modalities in cancer treatment, demonstrating the enduring impact of his work in the scientific community.

Profile summary based on public USPTO records.